News

Izana Bioscience’s drug namilumab announced in major UK COVID-19 drugs trial

Find our press release as a PDF here in addition to being found below. First investigational drug selected for testing in innovative CATALYST clinical trial programme in 12 UK centres led by University Hospitals Birmingham, Europe’s largest integrated critical care centre   Investigational therapy developed to treat rheumatoid arthritis could be potential therapy for hospitalised COVID-19 patients…

Read More

Initiation of two-centre compassionate use study involving namilumab in the treatment of individual patients with rapidly worsening COVID-19 infection in Italy

Find our press release as a PDF here in addition to being found below. Emergency access granted to investigational therapy Objective to treat rapidly deteriorating COVID-19 patients before ICU admission and prior to ventilation Discussions with international regulators, KOLs and clinical centres of excellence are ongoing to progress namilumab OXFORD, England, April 06, 2020 – Izana…

Read More

Izana Bioscience Initiates Namilumab Phase II Proof-Of-Concept Clinical Study In Ankylosing Spondylitis

Oxford, UK – 13 August 2018:  Izana Bioscience, a biopharmaceutical company focused on translational medicine, today announced the initiation of a phase II proof-of-concept clinical study of namilumab in ankylosing spondylitis, a debilitating arthritic disease of the spine that affects millions of people worldwide. The randomized, double-blind, placebo-controlled NAMASTE study (Namilumab in Ankylosing Spondylitis Therapy) will enrol over 40…

Read More

Izana Bioscience Launches As New Clinical-Stage Translational Medicine Company Developing Namilumab In Ankylosing Spondylitis

Find our press release as a PDF here in addition to being found below. Namilumab exclusive worldwide licence granted by Takeda Awarded £1.35 million grant by Innovate UK to support phase II proof-of-concept study Highly experienced management team; co-founded by serial entrepreneur Bryan Morton Oxford, UK – 14 December 2017:  Izana Bioscience (“Izana” or “the Company”) launches…

Read More